Long A&E waits linked to more than 1,300 extra deaths a month in England

Accident and emergency waiting times have long been one of the most visible capacity issues facing the National Health Service in England. A fresh analysis carried by the Guardian, drawn up by the Royal College of Emergency Medicine (RCEM), suggests that prolonged A&E waits can be linked to more than 1,300 additional deaths a month in England.
RCEM's analysis builds on a 2024 study which examined the relationship between long A&E waits and mortality. That study found that waits of eight hours or more in A&E were associated with one additional death for every 67 patients beyond the expected rate. RCEM has applied the same model to recent monthly NHS data to produce its current estimate.
NHS England's April figures showed that 26 percent of A&E patients waited longer than the four-hour target. The same data indicated that the number of patients waiting 12 hours or more for admission to an inpatient bed reached approximately 152,000. Hospital bed occupancy continues to sit above 92 percent.
Dr Adrian Boyle, RCEM's president, told the Guardian that the calculation was "not a rough estimate but a real, measurable model of patient harm." He warned that the numbers could rise further over summer if rapid triage and rapid-discharge practices are not improved.
An NHS England spokesperson said the long-standing pressure was multifactorial, pointing to bottlenecks in care home beds and shortages of allied health professionals. The office of Health Secretary Wes Streeting said 5,000 new emergency-care beds would come online by the end of the year. Critics say the rollout timetable is questionable.
Experts emphasise that the problem is not confined to A&E itself. One reason patients become stranded inside hospitals is that those classed as "medically ready for discharge" cannot be moved to home care or care-home beds. Roughly 14,000 patients fall into this category each day in England.
Compared with neighbouring health systems, average A&E waits in Germany and the Netherlands have also risen over the past three years, but the modelled excess deaths in those systems are lower than in the English model. Some of the difference is attributed to bed capacity and social care supply.
On reform, RCEM proposes that the four-hour standard be reinstated as a hard target and that performance metrics linked to onward transfer times from A&E be brought back. The Royal College of Nursing has called for fast recovery of lost nursing posts. The government has flagged up to GBP 4 billion of additional spending on social care reform in the autumn budget.
For patients, prolonged waits affect not only mortality risk but also the quality of treatment planning. Minutes matter in heart attack, sepsis, stroke and intra-abdominal emergencies. The RCEM report also says streaming protocols, used by clinicians to speed up patient prioritisation, need to be standardised across trusts.
The Guardian's framing makes clear that A&E waits have become an indicator of a structural capacity problem in the English NHS. There is broad agreement that the solution requires simultaneous attention to discharge speed, bed capacity and social care supply; the debate is over sequence and cost. This is not medical advice.
Read next

Scientists identify a new Alzheimer's trigger and a drug candidate that blocks it
Science Daily reports the identification of an enzyme that acts as a pathological trigger in Alzheimer's disease in animal models, alongside a drug candidate that blocks it with promising results. The study opens a therapeutic door beyond the amyloid-focused approach.

Congo Ebola outbreak: health workers labour with little pay and rest
STAT News reports that health workers at the centre of the DR Congo Ebola outbreak are coping with low pay, limited rest cycles and shortages of vaccines. The piece highlights the critical role of international funding and vaccine supply in containing the outbreak.

Johnson & Johnson enters the KRAS cancer race with a $1 billion Firefly deal
STAT News reports that Johnson & Johnson is paying close to $1 billion for the small biotech Firefly Bio, giving the pharma giant a foothold in KRAS, an oncology target once considered undruggable. The move accelerates competition with companies that have already brought KRAS inhibitors to market.

How Eriksen's heart device worked: living and competing with an ICD
The BBC explains how the implantable cardioverter-defibrillator (ICD) inside Christian Eriksen kicked into action during a Denmark friendly, and how cardiologists clear athletes to keep training and competing once one is fitted.

New drug aims to stop muscle-loss side effect of obesity injections
The BBC compiles new trial data on muscle-preserving agents being tested alongside GLP-1 obesity drugs such as semaglutide and tirzepatide. Early studies suggest the combinations can keep fat loss high while sharply reducing the loss of lean tissue that has worried doctors.
